FDA Warning Letter: QA Directed Vendor to Alter Electronic Batch Records After OOS Stability Results

FDA issued a Warning Letter to Jubilant HollisterStier (Spokane, WA) on January 9, 2025, documenting systematic data integrity failures in electronic batch record systems. The violations center on quality assurance personnel instructing a contract testing laboratory to modify stability test results retroactively after out-of-specification (OOS) results appeared — a direct breach of 21 CFR Part 211.194(a) and current good manufacturing practice requirements. For wholesale drug distributors qualifying pharmaceutical manufacturers as trading partners under DSCSA, this case demonstrates why electronic batch record integrity audits must extend beyond the manufacturer's own systems to encompass contract testing arrangements.

Regulatory Context

Electronic batch records fall under 21 CFR Part 211.188 (batch production and control records) and 21 CFR Part 11 (electronic records and electronic signatures). Part 211.194(a) specifically requires that laboratory records include complete data derived from all tests necessary to ensure compliance with established specifications and standards. When stability testing is performed by contract laboratories, the sponsor manufacturer retains full responsibility for data integrity in those records under 21 CFR Part 211.194(a)(2).

FDA's January 2025 Warning Letter cites Jubilant HollisterStier for failures across three core areas:

1. Directing a contract laboratory to delete and re-enter stability test results after OOS readings
2. Failing to investigate multiple temperature excursions in stability chambers
3. Inadequate quality unit oversight of electronic batch record modifications

The violations occurred between 2022 and 2024 across multiple product lots, indicating systemic rather than isolated failures.

Key Details from the Warning Letter

FDA investigators documented that Jubilant's quality assurance unit instructed the contract testing laboratory (not named in the letter) to modify electronic stability data after initial test results fell outside specification limits. The specific sequence:

1. Contract lab reported OOS stability results for active pharmaceutical ingredient potency
2. Jubilant QA personnel directed the lab to delete the original entries in the electronic system
3. Lab re-entered data with "corrected" values that met specifications
4. Original OOS results were not retained in the audit trail or investigation file

The Warning Letter notes that the firm's electronic record system did capture these modifications in metadata, which is how FDA detected the pattern during inspection. However, Jubilant failed to investigate why the alterations occurred and did not implement corrective actions to prevent recurrence.

FDA also cited inadequate investigation of stability chamber temperature excursions. Between January 2023 and August 2024, the firm documented 47 temperature deviations in stability chambers storing product used for ongoing studies. The firm's response: adjust alarm limits rather than investigate root cause or assess product impact.

Impact on Wholesale Distributor Vendor Qualification

Wholesale drug distributors conducting vendor qualification audits under DSCSA trading partner requirements (21 USC 360eee-1(b)) must verify manufacturer compliance with cGMP. Electronic batch record integrity is a core element of that verification.

Three operational implications for distributor QA teams:

Contract testing oversight: When qualifying a manufacturer, confirm their quality agreement with contract testing labs includes data integrity provisions. Request documentation showing the manufacturer reviews contract lab electronic systems for Part 11 compliance and audit trail functionality.

Stability data access: During vendor audits, request access to stability study protocols and electronic records. Verify that OOS investigations include a review of electronic audit trails showing who entered data, when, and whether any modifications occurred post-entry.

Temperature excursion protocols: Distributors managing cold chain products should verify manufacturer stability programs include defined temperature excursion limits and investigation triggers. A manufacturer that adjusts alarm setpoints rather than investigating excursions presents elevated risk for product shipped under similar conditions.

This Warning Letter does not indicate that Jubilant's distributed product was adulterated, but FDA explicitly states the firm has not demonstrated their quality system is capable of preventing future data integrity failures. Distributors carrying products manufactured at this facility should request the firm's corrective action plan and verify implementation before accepting new lots.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 pharmaceutical wholesale distributors and 3PLs across 51 jurisdictions. Of these, 1,234 hold active FDA registration — a baseline requirement for entities handling prescription drug products. However, FDA registration alone does not indicate whether an entity's trading partners maintain adequate electronic batch record systems or data integrity controls.

The average compliance score across all tracked entities is 51/100, placing the majority in the "Fair" tier (919 entities). This score reflects verified signals across state licensure, NABP accreditation, FDA registration, and enforcement history — but does not currently include manufacturer cGMP compliance or contract testing oversight. Electronic batch record integrity sits upstream of distributor operations: manufacturers and contract labs produce the data, distributors rely on it during vendor qualification.

The 73 entities in ColdChainCheck's directory with FDA recalls on record demonstrate that enforcement actions, while public, are not systematically tracked by most procurement teams. This Warning Letter against Jubilant HollisterStier will not appear in ColdChainCheck's distributor compliance scores — Jubilant is a manufacturer, not a wholesale distributor — but distributors carrying Jubilant-manufactured products should document their response in vendor files.

Practical Guidance for QA Managers

• Check your manufacturer roster: If your facility distributes or stores products manufactured by Jubilant HollisterStier (Spokane, WA), request a copy of their corrective action plan in response to the January 2025 Warning Letter. Verify the plan addresses electronic batch record modification controls and contract lab oversight.

• Review vendor qualification protocols: Confirm your vendor audit checklist includes questions about electronic batch record systems, Part 11 compliance, and contract testing quality agreements. If you rely on third-party audits (ISO, NABP accreditation), verify those audits cover data integrity controls.

• Document trading partner compliance: DSCSA requires verification that trading partners are authorized and operate in compliance with federal and state requirements. Use the ColdChainCheck directory to confirm distributor partners hold active licenses and FDA registration. For manufacturers, request current cGMP inspection reports.

• Monitor contract testing arrangements: If you operate as a 3PL storing client-owned inventory, confirm your quality agreement specifies responsibility for stability study oversight and temperature excursion investigation. The Jubilant case shows that contract relationships do not reduce manufacturer accountability for data integrity.

For guidance on DSCSA vendor qualification requirements, see the DSCSA Compliance Checklist for Wholesale Distributors.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult legal counsel and verify all compliance requirements with the relevant federal and state authorities.